Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference

Core Viewpoint - Sagimet Biosciences Inc. is advancing its clinical-stage biopharmaceutical development, particularly focusing on the anti-fibrotic effects of its FASN inhibitor, denifanstat, in treating MASH patients [1][3]. Group 1: Clinical Trial and Presentation - Sagimet will present a poster at the 10th Annual MASH-TAG Conference, highlighting significant improvements in fibrosis for F3 MASH patients and biomarker enhancements in qFibrosis stage 4 MASH patients from the Phase 2b FASCINATE-2 trial [1][2]. - The poster presentation is scheduled for January 10, 2026, and will be delivered by Dr. Rohit Loomba from the University of California San Diego [2]. Group 2: Company Overview - Sagimet is focused on developing novel FASN inhibitors to address dysfunctional metabolic and fibrotic pathways, particularly in conditions linked to excessive palmitate production [3]. - Denifanstat has successfully met all primary endpoints in its Phase 2b FASCINATE-2 trial and is also being tested in a Phase 3 trial for moderate-to-severe acne in partnership with a licensee in China [3]. - The company is also developing a second oral FASN inhibitor, TVB-3567, which is currently undergoing a Phase 1 clinical trial [3]. Group 3: MASH Disease Context - MASH is a severe liver disease affecting over 265 million people globally, characterized by fat accumulation in the liver, inflammation, and fibrosis, leading to serious liver-related outcomes [4]. - There are limited approved treatments for non-cirrhotic MASH and none for MASH cirrhosis, highlighting a significant unmet medical need in this area [4].